Abstract
We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormonal therapy was retrieved from the Duke Prostate Center database. Age, prostate-specific antigen (PSA), pathological Gleason score (pG), lymph node status, seminal vesicle invasion (SVI), extracapsular extension (ECE), positive surgical margin (PSM) status, year of surgery, race, adjuvant radiation therapy (XRT), percent tumor involvement in the RP specimen and prostate weight were evaluated as possible predictors of BCR in multivariate Cox regression analysis. BCR was defined as a PSA of 0.2 ng ml−1 or higher at least 30 days after surgery. A nomogram was developed from the Cox model. Predictive accuracy was obtained by calculating bias-corrected Harrell's c and by bootstrap calibration. In multivariate analysis, PSA (hazard ratio 1.39 (95% confidence interval 1.29–1.51)), ECE (1.22 (1.04–1.44)), pG score (1.38 (1.14–1.68), 2.23 (1.76–2.84), 2.69 (2.12–3.40) for pG 3+4, 4+3, >7, respectively), SVI (1.72 (1.40–2.12)), PSM (2.05 (1.73–2.42)), year of surgery (0.65 (0.54–0.77)), African-American race (1.37 (1.13–1.66)), adjuvant XRT (0.19 (0.11–0.34)) and prostate weight (0.83 (0.76–0.92)) were identified as independent predictors of BCR (P⩽0.018 for all factors). Predictive accuracy of the nomogram was 0.75. Race and prostate weight were independent predictors for BCR after RP. By incorporating these variables, we developed a nomogram, which provides a highly accurate means for estimating risk of BCR after RP.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Freedland SJ, Moul JW . Prostate specific antigen recurrence after definitive therapy. J Urol 2007; 177: 1985–1991.
Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr FJ, Dotan ZA, Fearn PA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715–717.
Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr FJ, Dotan ZA, DiBlasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005–7012.
Kattan MW, Wheeler TM, Scardino PT . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499–1507.
Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ . Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110: 906–910.
R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2007. http://www.R-project.org.
Harrell FE . Design: Design Package. R package version 2.1-1 2007.
Harrell FE . Hmisc: Harrell Miscellaneous. R package version 3.4-2 2007.
Hamilton RJ, Aronson WJ, Presti Jr JC, Terris MK, Kane CJ, Amling CL et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer 2007; 110: 2202–2209.
Iselin CE, Box JW, Vollmer RT, Layfield LJ, Robertson JE, Paulson DF . Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 1998; 83: 2353–2360.
Eastham JA, Kattan MW . Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000; 163: 143–145.
Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002; 20: 2863–2868.
Sohayda CJ, Kupelian PA, Altsman KA, Klein EA . Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol 1999; 162: 1331–1336.
Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 2006; 176: 515–519.
Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology 2002; 59: 907–912.
Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR . Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 2002; 168: 2510–2515.
Tarman GJ, Kane CJ, Moul JW, Thrasher JB, Foley JP, Wilhite D et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology 2000; 56: 1016–1020.
Moul JW, Douglas TH, McCarthy WF, McLeod DG . Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996; 155: 1667–1673.
Powell IJ, Banerjee M, Bianco FJ, Wood Jr DP, Dey J, Lai Z et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol 2004; 171: 1508–1512.
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439–445.
Zorn KC, Orvieto MA, Mikhail AA, Gofrit ON, Lin S, Schaeffer AJ et al. Effect of prostate weight on operative and postoperative outcomes of robotic-assisted laparoscopic prostatectomy. Urology 2007; 69: 300–305.
Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005; 23: 7546–7554.
Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM . Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000; 163: 1155–1160.
Foley CL, Bott SR, Thomas K, Parkinson MC, Kirby RS . A large prostate at radical retropubic prostatectomy does not adversely affect cancer control, continence or potency rates. BJU Int 2003; 92: 370–374.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A . A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 1998; 52: 631–636.
Msezane LP, Gofrit ON, Lin S, Shalhav AL, Zagaja GP, Zorn KC . Prostate weight: an independent predictor for positive surgical margins during robotic-assisted laparoscopic radical prostatectomy. Can J Urol 2007; 14: 3697–3701.
Nixon RG, Meyer GE, Brawer MK . Differences in prostate size between patients from University and Veterans Affairs Medical Center populations. Prostate 1999; 38: 144–150.
Terris MK, Prestigiacomo AF, Stamey TA . Comparison of prostate size in university and veterans affairs health care system patients with negative prostate biopsies. Urology 1998; 51: 412–414.
Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007; 99: 1171–1177.
Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–578.
Thompson Jr IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329–2335.
Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178–4186.
Acknowledgements
We thank Donna E Levy for help with the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schroeck, F., Sun, L., Freedland, S. et al. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 11, 371–376 (2008). https://doi.org/10.1038/pcan.2008.18
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2008.18
Keywords
This article is cited by
-
Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men
Prostate Cancer and Prostatic Diseases (2023)
-
Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
World Journal of Surgical Oncology (2018)
-
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
Prostate Cancer and Prostatic Diseases (2010)